An experimental GlaxoSmithKline treatment for multiple myeloma has achieved the main goal of a key study, and the drug maker plans to file for regulatory approval by the end of this year.

GlaxoSmithKline (NYSE: GSK) said Friday that treatment with its drug, belantamab mafodotin, showed a “clinically meaningful overall response rate” in the study. The British pharmaceutical company did not report additional details other than to say that its safety and tolerability were consistent with an earlier test of the drug.

Results from the earlier Phase 1 test were published in March in the Blood Cancer Journal. The data showed… Read more »